SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a crypto embodying cannabis culture, community, and freedom. Community members emphasize its focus on positivity, long-term vision, and real-world applications within the cannabis space. The conversation highlights Weedcoin as more than just a token, but as a movement for culture and community.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to recent Phase 3 trial data for their skin drug, Sonelokimab, which showed mixed results. While one trial succeeded, another was impacted by a high placebo response, leading to community discussion around potential regulatory implications and future prospects. Community members are actively debating the approvability of the drug, potential buyout scenarios, and comparing it to competitors in the sector.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as investors discuss potential catalysts for cannabis stocks, including regulatory reform and rescheduling. Community members are debating whether to buy and hold for long-term growth or trade on short-term price movements, while some are expressing frustration with the ETF's performance relative to its underlying assets. The broader context involves speculation around political developments and potential shifts in market sentiment towards the cannabis sector.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, leading to significant after-hours price movement. Community discussions revolve around the stock's small float, potential for a squeeze, and the impact of warrants associated with the deal. Some traders are optimistic about continued upward momentum, while others express concerns about potential dilution.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as community members discuss the potential impact of cannabis rescheduling following supportive comments from former President Trump. Investors are weighing potential benefits like tax relief and uplisting to major exchanges against the risk of political delays. Community members are closely watching for further developments and anticipating a potential surge in the stock price.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to recent surges in volume and price, sparking speculation about a potential short squeeze or upcoming news catalyst. Community discussions revolve around the possibility of significant upside, comparing it to similar stocks with low floats, while also referencing analyst upgrades and price target increases. The stock's volatility and potential for further gains are key talking points.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as the community discusses the potential impact of cannabis rescheduling following Trump's recent comments and a new $50 million share repurchase program. Community talking points include tax relief, increased profitability for US cannabis companies, and advantages over Canadian competitors. Some investors view GTBIF as a strong, profitable US-based company poised to benefit from regulatory changes.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending due to the appointment of Barbara Humpton as the new CEO, effective October 1, 2025; the community is discussing her extensive experience and the company's strategic focus on becoming a leading supplier of rare earth minerals and magnets. Conversations also involve speculation around government deals and potential investment, along with options activity and price targets.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as investors weigh the potential impact of a looming government shutdown and upcoming jobs data. Community chatter revolves around market resilience, potential for a significant pullback, and debate over whether current valuations are justified. Some are pointing to technical indicators and historical patterns, while others focus on macro factors like inflation and Fed policy.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending after Genmab announced its acquisition of the company for $97 per share, a deal valued at $8 billion, to gain access to a promising head and neck cancer drug. The community is buzzing about the buyout price and the strategic implications for Genmab as it aims to become a global biotech leader. Some traders are expressing regret for previously selling their shares while others are eyeing similar companies as potential takeover targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for September 19th

LRN, RL, GFI, CFBK and M have been added to the Zacks Rank #1 (Strong Buy) List on September 19, 2025.

New Strong Buy Stocks for September 2nd

RSI, UDMY, NVST, DORM and CFBK have been added to the Zacks Rank #1 (Strong Buy) List on September 2, 2025.

New Strong Buy Stocks for August 13th

CFBK, JBL, ANET, RL and NGG have been added to the Zacks Rank #1 (Strong Buy) List on August 13, 2025.

Best Value Stocks to Buy for August 13th

JBL, CFBK and MSBHF made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 13, 2025.

Blue Foundry Bancorp (BLFY) Reports Q2 Loss, Tops Revenue Estimates

Blue Foundry Bancorp (BLFY) delivered earnings and revenue surprises of +9.09% and +1.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MVB Financial (MVBF) Q2 Earnings and Revenues Miss Estimates

MVB Financial (MVBF) delivered earnings and revenue surprises of -51.61% and -6.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Esquire Financial Holdings, Inc. (ESQ) Matches Q2 Earnings Estimates

Esquire Financial (ESQ) delivered earnings and revenue surprises of 0.00% and +3.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Hanover Bancorp, Inc. (HNVR) Misses Q2 Earnings and Revenue Estimates

Hanover Bancorp (HNVR) delivered earnings and revenue surprises of -42.11% and -3.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES QUARTERLY CASH DIVIDEND PR Newswire COLUMBUS, Ohio, Jan. 6, 2025...

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES 17% INCREASE IN ITS QUARTERLY CASH DIVIDEND

CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES 17% INCREASE IN ITS QUARTERLY CASH DIVIDEND CF BANKSHARES INC., PARENT OF CFBANK, NA, ANNOUNCES 17% INCREASE IN ITS QUARTERLY CASH DIVIDEND PR...

CF Bankshares, Inc. operates as a financial holding company which is engaged in the provision of business banking products and services. Its products and services include commercial loans and leases, commercial and residential real estate loans and treasury management depository services. It operates through the Real Estate and Consumer segments. The company was founded in September 1998 and is headquartered in Columbus, OH.

CF Bankshares Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$24.30
Prev Close	$24.30
Open	$24.42
Dividend Yield	0.98%
50-Day Moving Average	$24.37
Beta	0.38
Avg. Volume	23,804.76
PE Ratio	8.74

52-Week High	$31.17
52-Week Low	$19.22
Market Capitalization	$156.67M
EPS (Annual)	$2.06
Price to Book	0.89
Revenue Per Employee	$1.21M
Enterprise Value/EBITDA	N/A

CFBK
CF Bankshares Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CFBK News

CFBK CF Bankshares Inc